Beijing Biopharma Sales Up 22% To RMB 25.5 Billion
This article was originally published in PharmAsia News
Beijing's biopharmaceutical sales reached RMB 25.51 billion ($3.99 billion) for the first half of 2011, up 22 percent
You may also be interested in...
The US company is bringing extra supplies of lopinavir/ritonavir into France but stresses that the combination treatment is not authorized for treating patients with the coronavirus.
GSK commits to investing behind OTC and oral health brands in India after offloading nutrition assets to Unilever.
The Belgian biotech has managed to attract considerable sums from venture capitalists over the past couple of years amid hopes that its two next-generation immunotherapies will be best-in-class agents.